MedPath

EXPLORE. Multi-center, randomized trial to study the impact of percutaneous coronary intervention on left ventricular function in patients with a non-infarct related chronic total occlusion after ST-elevation myocardial infarction: PCI vs. conservative approach in CTO patients after STEMI.

Recruiting
Conditions
1. ST-elevation myocardial infarction (STEMI)
<br />NLD:<br />ST-elevatie myocard infarct (STEMI),<br />percutane coronaire interventie,<br />chronische totale occlusie,<br />linker ventrikel functie.
<br />3. Chronic total occlusion
<br />4. left ventricular function
<br />2. percutaneous coronary intervention
Registration Number
NL-OMON24093
Lead Sponsor
Investigator initiated studyAcademic Medical Center ¨C University of AmsterdamDepartment of cardiologyThe Netherlands Principal investigators:R.J. van der Schaaf, MDR.J. de Winter, MD, PhDJ.P. Henriques, MD, PhD
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
300
Inclusion Criteria

Patients after successful primary PCI for STEMI are screened for entry into this trial. A primary PCI is ¡®successful¡¯ when the residual stenosis of the culprit lesion < 50% and the TIMI flow ¡Ý 2.

Exclusion Criteria

1. Older than 80 years of age;

2. Persistent or permanent atrial fibrillation;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measured by cardiac MRI at four months:<br /><br>1. Left ventricular ejection fraction;<br /><br>2. Left ventricular end-diastolic volume. <br>
Secondary Outcome Measures
NameTimeMethod
1. Left ventricular end-systolic volume measured by MRI at four months;<br /><br>2. Left ventricular remodeling parameters, left ventricular mass, and infarct size measured by MRI at four months;<br /> <br>3. Angiographic analysis of the treated CTO at one year (in patients with PCI of the CTO);<br /><br>4. Functional class according to the NYHA-Classification at 30 days, four months and one year;<br /><br>5. Major Adverse Cardiac Event, defined as cardiac death, myocardial infarction, or coronary bypass grafting after four months and one, two, three, four and five years;<br /><br>6. NT-proBNP at four months and at one year (relative to baseline);<br /><br>7. Heart rate-adjusted QT duration measured by resting electrocardiography at four months and one year (relative to baseline).<br>
© Copyright 2025. All Rights Reserved by MedPath